Velusetrag improves diabetic, idiopathic gastroparesis

SAN DIEGO — Velusetrag, an oral, highly selective 5-hydroxytryptamine receptor 4 agonist, effectively reduced symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis, according to research presented at Digestive Disease Week.
Braden Kuo, MD, of Massachusetts General Hospital, said that while prokinetic agents have shown to be helpful in patients with gastroparesis, many of the agents have cardiac side effects that are linked to neurologic issues, leaving long-term options for treatment limited.
“Velusetrag [Theravance Biopharma] is a potent and very

Source link

Related posts

Diet–microbiota interactions and personalized nutrition


Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients


Study IDs 'Standard' Chemo for BRCA, PALB2 Pancreatic Cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy